LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 246

Search options

  1. Article ; Online: Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic.

    Goldman, Jason D

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 72, Issue 11, Page(s) e844–e847

    MeSH term(s) COVID-19/drug therapy ; Health Personnel ; Humans ; Hydroxychloroquine/therapeutic use ; Pandemics ; Pre-Exposure Prophylaxis ; SARS-CoV-2
    Chemical Substances Hydroxychloroquine (4QWG6N8QKH)
    Keywords covid19
    Language English
    Publishing date 2020-11-06
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa1707
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Perspectives on COVID-19 and cancer immunotherapy: a review series.

    Goldman, Jason D / Ascierto, Paolo Antonio

    Journal for immunotherapy of cancer

    2021  Volume 9, Issue 3

    MeSH term(s) Humans ; COVID-19/complications ; COVID-19/immunology ; COVID-19/virology ; Disease Management ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Neoplasms/complications ; Neoplasms/immunology ; Neoplasms/therapy ; Review Literature as Topic ; SARS-CoV-2
    Language English
    Publishing date 2021-03-11
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2021-002489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Hydroxychloroquine for Prevention of SARS-CoV-2 Infection

    Goldman, Jason D

    Clinical Infectious Diseases ; ISSN 1058-4838 1537-6591

    challenges to trial conduct during the global pandemic

    2020  

    Keywords Microbiology (medical) ; Infectious Diseases ; covid19
    Language English
    Publisher Oxford University Press (OUP)
    Publishing country uk
    Document type Article ; Online
    DOI 10.1093/cid/ciaa1707
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.

    Goldman, Jason D / Diaz, George / Urba, Walter J

    International journal of antimicrobial agents

    2021  Volume 57, Issue 1, Page(s) 106174

    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; Antiviral Agents/therapeutic use ; Azithromycin/therapeutic use ; COVID-19/drug therapy ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Humans ; Hydroxychloroquine/therapeutic use ; Politics ; SARS-CoV-2/pathogenicity ; Uncertainty
    Chemical Substances Anti-Bacterial Agents ; Antimalarials ; Antiviral Agents ; Drug Combinations ; Hydroxychloroquine (4QWG6N8QKH) ; Azithromycin (83905-01-5)
    Language English
    Publishing date 2021-01-06
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2020.106174
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Racial Disproportionality in Covid Clinical Trials.

    Goldman, Jason D / Osinusi, Anu / Marty, Francisco M

    The New England journal of medicine

    2020  Volume 383, Issue 25, Page(s) 2486–2487

    MeSH term(s) COVID-19 ; Child ; Clinical Trials as Topic ; Humans ; Racial Groups ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-11-06
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2029374
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

    Goldman, Jason D / Julian, Kathleen

    Clinical transplantation

    2019  Volume 33, Issue 9, Page(s) e13507

    Abstract: These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of urinary tract infections (UTI) in solid organ transplantation, focusing on kidney ... ...

    Abstract These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of urinary tract infections (UTI) in solid organ transplantation, focusing on kidney transplant (KT) recipients. KT recipients have unique risk factors for UTI, including indwelling stents and surgical manipulation of the genitourinary tract. KT recipients experience multi-drug antibiotic-resistant infections-UTI prevention and management strategies must consider risks of antimicrobial resistance. Non-antimicrobial prevention strategies for UTI in KT recipients are reviewed. It is important to recognize that some renal transplant recipients with UTI may primarily present with fever, malaise, leukocytosis, or a non-specific sepsis syndrome without symptoms localized to the urinary tract. However, asymptomatic bacteriuria (AB) must be distinguished from UTI because AB is not necessarily a disease state. Accumulating data indicate that there are no benefits of antibiotics for treatment of AB in KT recipients more than 2 months after post-transplant. Further research is needed on management of AB in the early (<2 months) post-transplant period, prophylaxis for UTI in this era of antibiotic resistance, recurrent UTI, non-antimicrobial prevention of UTI, and uropathogens identified in donor urine and/or preservative fluid cultures.
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Humans ; Organ Transplantation/adverse effects ; Practice Guidelines as Topic/standards ; Societies, Medical ; Urinary Tract Infections/diagnosis ; Urinary Tract Infections/drug therapy ; Urinary Tract Infections/etiology
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2019-03-28
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 639001-8
    ISSN 1399-0012 ; 0902-0063
    ISSN (online) 1399-0012
    ISSN 0902-0063
    DOI 10.1111/ctr.13507
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Prediction of HLA genotypes from single-cell transcriptome data.

    Solomon, Benjamin D / Zheng, Hong / Dillon, Laura W / Goldman, Jason D / Hourigan, Christopher S / Heath, James R / Khatri, Purvesh

    Frontiers in immunology

    2023  Volume 14, Page(s) 1146826

    Abstract: The human leukocyte antigen (HLA) locus plays a central role in adaptive immune function and has significant clinical implications for tissue transplant compatibility and allelic disease associations. Studies using bulk-cell RNA sequencing have ... ...

    Abstract The human leukocyte antigen (HLA) locus plays a central role in adaptive immune function and has significant clinical implications for tissue transplant compatibility and allelic disease associations. Studies using bulk-cell RNA sequencing have demonstrated that HLA transcription may be regulated in an allele-specific manner and single-cell RNA sequencing (scRNA-seq) has the potential to better characterize these expression patterns. However, quantification of allele-specific expression (ASE) for HLA loci requires sample-specific reference genotyping due to extensive polymorphism. While genotype prediction from bulk RNA sequencing is well described, the feasibility of predicting HLA genotypes directly from single-cell data is unknown. Here we evaluate and expand upon several computational HLA genotyping tools by comparing predictions from human single-cell data to gold-standard, molecular genotyping. The highest 2-field accuracy averaged across all loci was 76% by arcasHLA and increased to 86% using a composite model of multiple genotyping tools. We also developed a highly accurate model (AUC 0.93) for predicting
    MeSH term(s) Humans ; Transcriptome ; Sequence Analysis, DNA ; HLA Antigens/genetics ; Histocompatibility Antigens Class I/genetics ; Genotype ; Histocompatibility Antigens Class II/genetics
    Chemical Substances HLA Antigens ; Histocompatibility Antigens Class I ; Histocompatibility Antigens Class II
    Language English
    Publishing date 2023-04-25
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1146826
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults.

    Levy, Matthew E / Burrows, Evanette / Chilunda, Vanessa / Pawloski, Pamala A / Heaton, Phillip R / Grzymski, Joseph / Goldman, Jason D / McEwen, Lisa M / Wyman, Dana / Dei Rossi, Andrew / Dai, Hang / Isaksson, Magnus / Washington, Nicole L / Basler, Tracy / Tsan, Kevin / Nguyen, Jason / Ramirez, Jimmy / Sandoval, Efren / Lee, William /
    Lu, James / Luo, Shishi

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2024  

    Abstract: Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were ... ...

    Abstract Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.
    Language English
    Publishing date 2024-01-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciad796
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: The acute care burden of asthma in children was profoundly reduced during the COVID-19 pandemic: A multi-centre Canadian retrospective study.

    McConnery, Jason R / Bone, Jeffrey N / Goldman, Ran D / Hicks, Anne / Seaton, Claire / Subbarao, Padmaja / Moraes, Theo J

    Paediatrics & child health

    2023  Volume 29, Issue 2, Page(s) 98–103

    Abstract: Objectives: Asthma is a chronic lung condition that can be exacerbated when triggered by viruses. Pandemic public health restrictions aimed to reduce COVID-19 transmission indirectly effected other circulating viruses. This study assessed the impact of ... ...

    Abstract Objectives: Asthma is a chronic lung condition that can be exacerbated when triggered by viruses. Pandemic public health restrictions aimed to reduce COVID-19 transmission indirectly effected other circulating viruses. This study assessed the impact of the pandemic and associated public health measures on acute paediatric asthma across four tertiary sites in three Canadian provinces. We queried whether pandemic-related changes would impair preventive care and delay presentation to care, increasing asthma exacerbation severity.
    Methods: This retrospective study compared the frequency of acute care access and severity of presentation to emergency departments (ED) for acute asthma to four tertiary care children's hospitals during the COVID-19 pandemic (from March 17, 2020 to June 30, 2021) to a pre-lockdown control period (July 1, 2018 to March 16, 2020). Data was subjected to interrupted time series and Chi-square analysis.
    Results: Our study included 26,316 acute asthma visits to ED. Sites experienced a 63% to 89% reduction in acute asthma visits during the pandemic, compared with pre-lockdown controls, and a 17% to 85% reduction in asthma, that is out of proportion as a fraction of all-cause ED visits. For asthma, there was no difference in severity measured by rate of ward admission or rate of Paediatric Intensive Care Unit (PICU) admission.
    Conclusions: Public health measures appear to have resulted in a specific protective association on acute asthma with reduced acute care utilization over and above the reduction in all-cause presentations, without an increase in severity upon presentation. Our study indicates an importance to antiviral public health and engineering strategies to reduce viral transmission and thereby asthma morbidity.
    Language English
    Publishing date 2023-06-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 2106767-3
    ISSN 1918-1485 ; 1205-7088
    ISSN (online) 1918-1485
    ISSN 1205-7088
    DOI 10.1093/pch/pxad037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.

    Goldman, Jason D / Robinson, Philip C / Uldrick, Thomas S / Ljungman, Per

    Journal for immunotherapy of cancer

    2021  Volume 9, Issue 6

    Abstract: SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly variable disease severity and a bimodal course characterized by acute respiratory viral infection followed by hyperinflammation in a subset of patients with severe disease. ...

    Abstract SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly variable disease severity and a bimodal course characterized by acute respiratory viral infection followed by hyperinflammation in a subset of patients with severe disease. This immune dysregulation is characterized by lymphocytopenia, elevated levels of plasma cytokines and proliferative and exhausted T cells, among other dysfunctional cell types. Immunocompromised persons often fare worse in the context of acute respiratory infections, but preliminary data suggest this may not hold true for COVID-19. In this review, we explore the effect of SARS-CoV-2 infection on mortality in four populations with distinct forms of immunocompromise: (1) persons with hematological malignancies (HM) and hematopoietic stem cell transplant (HCT) recipients; (2) solid organ transplant recipients (SOTRs); (3) persons with rheumatological diseases; and (4) persons living with HIV (PLWH). For each population, key immunological defects are described and how these relate to the immune dysregulation in COVID-19. Next, outcomes including mortality after SARS-CoV-2 infection are described for each population, giving comparisons to the general population of age-matched and comorbidity-matched controls. In these four populations, iatrogenic or disease-related immunosuppression is not clearly associated with poor prognosis in HM, HCT, SOTR, rheumatological diseases, or HIV. However, certain individual immunosuppressants or disease states may be associated with harmful or beneficial effects, including harm from severe CD4 lymphocytopenia in PLWH and possible benefit to the calcineurin inhibitor ciclosporin in SOTRs, or tumor necrosis factor-α inhibitors in persons with rheumatic diseases. Lastly, insights gained from clinical and translational studies are explored as to the relevance for repurposing of immunosuppressive host-directed therapies for the treatment of hyperinflammation in COVID-19 in the general population.
    MeSH term(s) COVID-19/epidemiology ; COVID-19/immunology ; COVID-19/therapy ; Comorbidity ; Drug Repositioning/methods ; Drug Repositioning/statistics & numerical data ; HIV Infections/epidemiology ; HIV Infections/immunology ; Hematologic Neoplasms/epidemiology ; Hematologic Neoplasms/therapy ; Hematopoietic Stem Cell Transplantation/statistics & numerical data ; Humans ; Immunocompromised Host/physiology ; Immunosuppressive Agents/therapeutic use ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Immunotherapy/statistics & numerical data ; Mortality ; Pandemics ; Prognosis ; Rheumatic Diseases/epidemiology ; SARS-CoV-2/physiology ; Transplant Recipients/statistics & numerical data
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2021-06-21
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2021-002630
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top